Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeuroVax for SPMS
NCT02149706Phase 2Unknown
- Sponsor
- Immune Response BioPharma, Inc.
- Start
- Mar 2020
- Primary completion
- Mar 2022
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing NeuroVax with Placebo (2 arms). Primary endpoint: Expanded Disability Status Scale at 48 Weeks. Status: unknown.
02
Drugs
IR208
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT02149706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02149706.